MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
May 27, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
May 21, 2020 16:05 ET
|
MacroGenics, Inc.
Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
May 13, 2020 17:10 ET
|
MacroGenics, Inc.
Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
May 05, 2020 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
April 29, 2020 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
April 28, 2020 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
April 28, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
April 27, 2020 00:05 ET
|
MacroGenics, Inc.
Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Departure of Chief Medical Officer
March 04, 2020 17:00 ET
|
MacroGenics, Inc.
Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
February 27, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...